Product Description
Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus. (Sourced from: https://www.merck.com/news/merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy-for-nonalcoholic-steatohepatitis-nash/)
Mechanisms of Action: GLP-1 Agonist,GcGr Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Canada, Chile, China, Colombia, Czech Republic, France, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Mexico, Peru, Portugal, Puerto Rico, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 12
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Hepatitis|Hepatitis, Alcoholic|Liver Cirrhosis|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis
Phase 1: Healthy Volunteers|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-6024-017 | P2 |
Recruiting |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2026-05-15 |
|
| jRCT2031240217 | P2 |
Not yet recruiting |
Liver Cirrhosis|Hepatitis |
2026-05-15 |
|
| MK-6024-017 | P2 |
Unknown Status |
Hepatitis |
2026-05-15 |
|
| MK-6024-013 | P2 |
Active, not recruiting |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2025-12-29 |